S5 Ep4: Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
Mar 01, 2024•19 min•Season 5Ep. 4
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
For the best experience, listen in Metacast app for iOS or Android